Exelixis Inc. (NASDAQ:EXEL) – William Blair lifted their Q3 2016 EPS estimates for Exelixis in a note issued to investors on Thursday. William Blair analyst J. Sonnier now anticipates that the firm will post earnings per share of ($0.07) for the quarter, up from their prior forecast of ($0.17). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Exelixis’ Q4 2016 earnings at ($0.02) EPS, FY2016 earnings at ($0.52) EPS, Q1 2017 earnings at $0.00 EPS, Q2 2017 earnings at ($0.01) EPS, Q3 2017 earnings at $0.01 EPS, Q4 2017 earnings at $0.04 EPS, FY2017 earnings at $0.04 EPS, FY2018 earnings at $0.34 EPS and FY2019 earnings at $0.54 EPS.
A number of other equities research analysts have also weighed in on EXEL. Cowen and Company reiterated an “outperform” rating on shares of Exelixis in a research note on Tuesday, June 7th. Leerink Swann reiterated an “outperform” rating and set a $8.00 target price on shares of Exelixis in a research note on Wednesday, May 25th. Stifel Nicolaus boosted their target price on shares of Exelixis from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Piper Jaffray Cos. reiterated a “neutral” rating and set a $8.00 target price (up from $5.00) on shares of Exelixis in a research note on Thursday, August 4th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $11.10.
Shares of Exelixis (NASDAQ:EXEL) opened at 13.55 on Monday. The company’s market cap is $3.12 billion. The company’s 50-day moving average price is $10.80 and its 200 day moving average price is $7.03. Exelixis has a 1-year low of $3.55 and a 1-year high of $13.66.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.11. The business had revenue of $36.25 million for the quarter, compared to the consensus estimate of $16.76 million. Exelixis’s quarterly revenue was up 353.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.22) EPS.
In other news, insider Gisela Schwab sold 42,338 shares of the company’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $11.00, for a total value of $465,718.00. Following the completion of the sale, the insider now directly owns 174,354 shares in the company, valued at approximately $1,917,894. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of the company. Rhenman & Partners Asset Management AB raised its stake in Exelixis by 41.3% in the first quarter. Rhenman & Partners Asset Management AB now owns 650,000 shares of the biotechnology company’s stock valued at $2,600,000 after buying an additional 190,000 shares during the period. Aperio Group LLC increased its position in shares of Exelixis by 4.1% in the first quarter. Aperio Group LLC now owns 87,515 shares of the biotechnology company’s stock valued at $350,000 after buying an additional 3,410 shares in the last quarter. Pacad Investment Ltd. purchased a new position in shares of Exelixis during the first quarter valued at $406,000. BlackRock Group LTD increased its position in shares of Exelixis by 12.4% in the first quarter. BlackRock Group LTD now owns 242,999 shares of the biotechnology company’s stock valued at $972,000 after buying an additional 26,863 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its position in shares of Exelixis by 2.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 5,329,318 shares of the biotechnology company’s stock valued at $21,317,000 after buying an additional 127,342 shares in the last quarter. Hedge funds and other institutional investors own 81.80% of the company’s stock.
Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.